Introduction
Whether calcitonin has an important role in maintaining skeletal integrity is not known.'2 One finding supporting such a role was the identification of a young male patient with severe osteoporosis who was completely deficient in calcitonin and has responded well to calcitonin replacement treatment over the past nine years. 3 We therefore considered the possibility that his calcitonin gene might be defective. As the C cells of the thyroid are not accessible for direct analysis of calcitonin gene expression we instead carried out a detailed structural study of the gene looking for any changes that might explain this failure to produce calcitonin.
Materials and methods
DNA was extracted from the patient's peripheral lymphocytes4 and after restriction enzyme digestion was analysed on Southern blots probed with labelled restriction fragments specific for either calcitonin or calcitonin gene related peptide. Probe fragments were derived from the clones phTB35 and phTB586 and contained only exon IV or exon V and VI sequences The calcitonin gene is complex and many details about how its expression is regulated remain unclear. Calcitonin is produced by proteolytic cleavage of a pre-prohormone, which also includes N and C terminal flanking peptides and a short signal peptide (fig 1) . In the calcitonin gene the sequences representing calcitonin messenger RNA are found in four blocks (exons): exon I contains non-coding sequences from the beginning of the messenger RNA, exon II encodes the signal peptide, exon III encodes the N terminal flanking peptide, and exon IV encodes calcitonin itself, the C terminal flanking peptide, and the non-coding sequences from the end of the messenger RNA. When calcitonin messenger RNA is being made the synthesis of RNA starts at exon I and continues through the entire gene, ending several thousand bases beyond the end of exon IV. This primary transcript is then cut and reassembled in a complex series of splicing reactions, which result in the formation of the mature messenger RNA, which includes only the sequences of the first four exons (fig 1) . expression of calcitonin gene related peptide largely unaffected seem more likely. The simplest such change would be an alteration to the DNA sequence of exon IV.
DNA SEQUENCE OF CALCITONIN GENE
As a first step in the analysis of our patient's calcitonin-calcitonin gene related peptide gene we looked for large structural changes in the region of exon IV by using the technique of Southern blotting (fig 2) . With this procedure changes can be seen in the lengths of restriction fragments of the DNA that may result from insertion or deletion of sequences in the region being analysed. The method provides a rapid analysis but is limited in that changes of fewer than 20 bases are not detectable. No differences, quantitative or qualitative, were seen between our patient's calcitonin gene and that ofcontrols. For a more detailed analysis we isolated the calcitonincalcitonin gene related peptide gene from DNA prepared from our patient's peripheral lymphocytes. The entire DNA sequence encoding pre-procalcitonin was determined and corresponded exactly with the published gene sequence. Further' analysis showed that the parts of the gene specific for calcitonin gene related peptide (exons V and VI) were also entirely normal.
We then focused on the regions important for the differential processing of messenger RNAs for calcitonin and calcitonin gene related peptide. During the process of splicing the precursor RNA is cleaved after one exon, and the intervening sequence (intron) then forms a looped structure before cleavage at the second exon, joining of the two exon sequences, and elimination of the intervening sequence (fig 3) . The important regions are those at the ends of the intervening sequence and at the branch point where the looped structure forms.'" In the particular case of the calcitonin-calcitonin gene related peptide gene cleavage of the precursor RNA at the end of the calcitonin exon (IV) is important in preventing the splice that leads to production of calcitonin gene related peptide" and further evidence suggests that the secondary structure ofthe precursor RNA is important in allowing its interaction with exon specific splicing factors. 12
Exon IV Exon V CCAGAGTCACCTTGGGuTTCTGACACCC-CTGGG Calcitonin gene *** ************* * * *** AGAGAAGACTCTTGGGTTTCTGATAGGCACTGAC Globin gene FIG 4-Altered calcitonin gene sequence from patient with osteoporosis. Sequence from intervening sequence between exons IV and V shows single base insertion, which is next to consensus sequence for formation of branch point (CTGAC (underlined)) and has homology with more extensive sequence from branch point in the (3 globin gene. Asterisks show identical residues in calcitonin and 3globin genes When our patient's DNA was sequenced no changes were found in these critical regions. The only difference between our sequence and the normal sequence was a single base insertion at position 462 in the intervening sequence between exons IV and V (fig 4) . Such a finding was not unexpected as non-coding sequences such as these commonly show differences (neutral polymorphisms) between individual people and these differences have no effect on the expression of the neighbouring genes. The extra base is, however, next to a CTGAC sequence, which is the consensus sequence for formation of a branch point during splicing.10 We searched the GENBANK database of DNA sequences for similar sequences. Out of more than 10 million bases in the database, the best fit was with a short sequence from the B globin gene, which has been shown to become resistant to ribonuclease during in vitro splicing and is the site for formation ofa branch point (fig 4) . '3 This homology indicates that the altered sequence in our patient may participate in splicing reactions. It is, however, unlikely to be the primary branch point site in this intervening sequence as these are generally much closer to the following exon sequence. Further studies with the gene in an in vitro expression system would be necessary to determine how any effect is produced. One possibility is that the altered sequence takes on the properties of a branch point, forcing an abortive splice which precludes the production of calcitonin.
Establishing a role for calcitonin in the aetiology of this patient's osteoporosis is of considerable importance. Although his condition is undoubtedly rare, the results suggest that calcitonin plays an important part in maintaining skeletal integrity, strengthening arguments in favour ofits use in treating osteoporosis in general.
